Applicable exploration of recombinant human endostatin on patientswith advanced prostatic carcinoma
10.7619/jcmp.201415021
- VernacularTitle:重组人血管内皮抑制素在晚期前列腺癌患者中的应用
- Author:
Guofu HUANG
1
;
Xiaoling LENG
Author Information
1. 新疆医科大学第五附属医院 放化疗科
- Keywords:
recombinant human endostatin;
prostatic carcinoma;
serum total prostate specific antigen;
free prostate specific antigen
- From:
Journal of Clinical Medicine in Practice
2014;(15):70-72
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical efficacy of long-term application of recombi-nant human endostatin on patients with advanced prostatic carcinoma.Methods Twenty-eight pa-tients with prostatic carcinoma were divided into control group (10 cases)treated with endocrine therapy and radiotherapy and experimental group (18 cases)added with recombinant human endo-statin.Serum total prostate specific antigen (TPSA)and free prostate specific antigen (FPSA)lev-els were detected and adverse responses were observed.Results FPSA and TPSA levels decreased evidently in both groups after treatment (P <0.01),and were obviously lower in experimental group than in control group 3,6,12 and 28 months after treatment (P <0.01).Additionally, their curve charts showed that their levels in each time point was lower in experimental group than in control group.The number of patients with myelosuppression in degrees Ⅱ and Ⅲ was markedly higher in experimental group than in control group (P <0.01),but there were no significant differ-ences in those with coagulation disorders and gastrointestinal responses (P >0.05).Liver function examination indicated that aspartate transaminase (AST)and alanine transaminase (ALT)had slight increase and were improved after liver-protection therapies,which had no significant differ-ences between two groups (P >0.05).Conclusion Combined application with recombinant human endostatin has better clinical efficacy than single utilization of endocrine therapy and radiotherapy on patients with advanced prostatic carcinoma,in which the myolesuppression is the primary adverse response.
